01/13/08

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	109/623,533	
Filing Date	September 5, 2000	
First Named Inventor	Dominique P. BRIDON	
Art Unit	1648	
Examiner Name	J. Parkin	
Attorney Docket Number	500862001520	

		_			
		<u></u>	U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (# known)}		· · · · · · · · · · · · · · · · · · ·	Figures Appear
	1	US-			
		US-	1 - 1		
	†	US-			
		US-			
		US	† †		
 		US-			
	†	US-			
		U\$-	1		**
	†	US-			
		US-			
		US-			
		US-			· · · · · · · · · · · · · · · · · · ·
	1	US-	†		
· · · · · · · · · · · · · · · · · · ·		US-	†		
		US-	†		
····	 	US-			

	-	FOREIG	ON PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	\prod
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	120
****	ļ					F
						┡
				•		<u> </u>
	_			l	İ	

Examiner Signature Date Considered 05/30/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include topy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Coduments at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for retaining this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

01/13/05

		Application number	09/623,533	
INFORMA	TION DISCLOSURE	Filing Date	September 5, 2000	
STATEMENT BY APPLICANT		First Named Inventor	Dominique P. BRIDON	
(Man an		Art Unit	1648	
(Use as many sheets as necessary)		Examiner Name	J. Parkin	
Sheet 2	of 2	Attorney Docket Number	500862001520	J

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of		
7		Christophe BOECKLER, "Immunogenicity of New Heterobifunctional Cross-Linking Reagents Used in the Conjugation", Journal of Immunological Methods, 1996, Vol. 191, pp. 1-10.		
		Carl WILD, "A synthetic Peptide Inhibitor of Human Immunodeficiency Virus Replication : Correlation", Proc. Natl. Acad. Sci., November 1992, Vol. 89, pp. 10537-10541.		
		Joseph G. SODROSKI, "HIV-1 Entry Inhibitors in the Side Pocket", Cell, October 29, 1999, Vol. 99, pp. 243-246.		
		Aran F. LABRIJN, "Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120" Journal of Virology, October 2003, Vol. 77, pp. 10557-10565.		
		Nasar M. QURESHI, "Characterization of a Putative Cellular Receptor for HIV-1 Transmembrane Glycoprotein Using Synthetic Peptides" AIDS, 1990, Vol. 4, pp. 553-558.		
	$\overline{}$		P	
Examiner	1	Date		
Signature		Considered 05/30/05		

^{*}EXAMINER: Initial/if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.